News Breaks |
|
|
| March 12, 2013 |
| 11:25 EDT |  | AMGN, AMGN, AZN, AZN, CELG, CELG, LLY, LLY, NVS, NVS, REGN, REGN, SNY, SNY, VRX, VRX | Leerink's biotech analysts hold an analyst/industry conference call
Following the recently held American Academy of Dermatology's Annual Meeting, Analysts Fernandez, Schwartz and Liang discuss new pipeline products with an emphasis on psoriasis and atopic dermatitis incluidng Celgene's apremilast and anti-IL-17 antibodies (NVS, LLY, AMGN/AZN) and REGN/SNY's dupilumab on an Analyst/Industry conference call to be held on March 12 at 12 pm. |
|
|
News For AMGN;AZN;CELG;LLY;NVS;REGN;SNY;VRX From The Last 14 Days Check below for free stories on AMGN;AZN;CELG;LLY;NVS;REGN;SNY;VRX the last two weeks. |
|
|
| May 23, 2013 |
| 08:18 EDT |  | SNY | Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi
 Subscribe for More Information |
|
| 07:37 EDT | | CELG | Celgene says FDA grants priority review for ABRAXANE sNDA
Subscribe for More Information |
|
| May 22, 2013 |
| 12:25 EDT |  | REGN | Stocks with call strike movement; GME REGN
Subscribe for More Information |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
|
| May 21, 2013 |
| 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). |
|
| 07:44 EDT | | NVS, SNY | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:24 EDT | | LLY, NVS | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 19:01 EDT | | REGN | On The Fly: After Hours Movers
Subscribe for More Information |
|
| 17:26 EDT | | REGN, SNY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 17:20 EDT | | REGN | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
| |
| 11:27 EDT | | SNY | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| 09:51 EDT | | CELG | Celgene management to meet with JPMorgan
Meetings to be held in Boston on May 22-23 hosted by JPMorgan. |
|
| 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| 07:28 EDT | | REGN | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 17, 2013 |
| 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information |
|
| 14:48 EDT |  | VRX | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | VRX | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 10:36 EDT | | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| 10:07 EDT |  | REGN | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. |
| |
|
|
|
|
